BACKGROUND: Both obesity and inflammatory bowel disease (IBD) are highly prevalent in Western societies. IBD, including Crohn's disease (CD) and ulcerative colitis (UC), has been historically associated with cachexia and malnutrition. It is uncertain how obesity, a chronic pro-inflammatory state, may impact the course of IBD. AIM: The aim of this study was to report the prevalence of obesity in patients with IBD in a metropolitan US population and to assess the impact of obesity on disease phenotypes, treatment, and surgical outcomes in IBD patients. METHODS: We reviewed the medical records of patients identified from the IBD registries of the Dallas Veterans Affairs Medical Center and Parkland Health and Hospital Systems who were seen from January 1, 2000, to December 31, 2012. RESULTS: Of 581 identified IBD patients, 32.7 % were obese (BMI ≥ 30) and 67.6 % were non-obese (BMI < 30). There were 297 (51.1 %) patients with CD and 284 (48.9 %) patients with UC. The rate of obesity was 30.3 % among CD patients and 35.2 % among UC patients. Overall, obese patients were significantly less likely to receive anti-TNF treatment, undergo surgery, or experience a hospitalization for their IBD than their non-obese counterparts (55.8 vs. 72.1 %, p = .0001). CONCLUSION: Obesity is highly prevalent in our IBD patients, paralleling the obesity rates in the US population. Clinical outcomes were significantly different in obese versus non-obese patients with IBD. Despite the plausible mechanisms whereby obesity might exacerbate IBD, we have found that obesity (as defined by BMI) is a marker of a less severe disease course in IBD.
BACKGROUND: Both obesity and inflammatory bowel disease (IBD) are highly prevalent in Western societies. IBD, including Crohn's disease (CD) and ulcerative colitis (UC), has been historically associated with cachexia and malnutrition. It is uncertain how obesity, a chronic pro-inflammatory state, may impact the course of IBD. AIM: The aim of this study was to report the prevalence of obesity in patients with IBD in a metropolitan US population and to assess the impact of obesity on disease phenotypes, treatment, and surgical outcomes in IBD patients. METHODS: We reviewed the medical records of patients identified from the IBD registries of the Dallas Veterans Affairs Medical Center and Parkland Health and Hospital Systems who were seen from January 1, 2000, to December 31, 2012. RESULTS: Of 581 identified IBD patients, 32.7 % were obese (BMI ≥ 30) and 67.6 % were non-obese (BMI < 30). There were 297 (51.1 %) patients with CD and 284 (48.9 %) patients with UC. The rate of obesity was 30.3 % among CDpatients and 35.2 % among UC patients. Overall, obesepatients were significantly less likely to receive anti-TNF treatment, undergo surgery, or experience a hospitalization for their IBD than their non-obese counterparts (55.8 vs. 72.1 %, p = .0001). CONCLUSION:Obesity is highly prevalent in our IBD patients, paralleling the obesity rates in the US population. Clinical outcomes were significantly different in obese versus non-obesepatients with IBD. Despite the plausible mechanisms whereby obesity might exacerbate IBD, we have found that obesity (as defined by BMI) is a marker of a less severe disease course in IBD.
Authors: Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren Journal: Can J Gastroenterol Date: 2005-09 Impact factor: 3.522
Authors: Millie D Long; Wallace V Crandall; Ian H Leibowitz; Lynn Duffy; Fernando del Rosario; Sandra C Kim; Mark J Integlia; James Berman; John Grunow; Richard B Colletti; Bess T Schoen; Ashish S Patel; Howard Baron; Esther Israel; George Russell; Sabina Ali; Hans H Herfarth; Christopher Martin; Michael D Kappelman Journal: Inflamm Bowel Dis Date: 2010-12-17 Impact factor: 5.325
Authors: Simon S M Chan; Robert Luben; Anja Olsen; Anne Tjonneland; Rudolf Kaaks; Birgit Teucher; Stefan Lindgren; Olof Grip; Timothy Key; Francesca L Crowe; Manuela M Bergmann; Heiner Boeing; Göran Hallmans; Pontus Karling; Kim Overvad; Domenico Palli; Giovanna Masala; Hugh Kennedy; Fiona vanSchaik; Bas Bueno-de-Mesquita; Bas Oldenburg; Kay-Tee Khaw; Elio Riboli; Andrew R Hart Journal: Am J Gastroenterol Date: 2013-01-15 Impact factor: 10.864
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059
Authors: S Kurnool; N H Nguyen; J Proudfoot; P S Dulai; B S Boland; N Vande Casteele; E Evans; E L Grunvald; A Zarrinpar; W J Sandborn; S Singh Journal: Aliment Pharmacol Ther Date: 2018-04-17 Impact factor: 8.171
Authors: Po-Hong Liu; Kristin E Burke; Ashwin N Ananthakrishnan; Paul Lochhead; Ola Olen; Jonas F Ludvigsson; James M Richter; Andrew T Chan; Hamed Khalili Journal: Clin Gastroenterol Hepatol Date: 2018-12-06 Impact factor: 11.382